Hypothetical molecular mechanisms by which local iron overload facilitates the development of venous leg ulcers and multiple sclerosis lesions

Medical Hypotheses

Volumn 71, Issue 2, 2008, Pages 293-297

  Simka, M ^a   Rybak, Z ^b  

^a Department of Angiology ^*  (Poland)

^b WROCLAW MEDICAL UNIVERSITY   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE; GAMMA INTERFERON RECEPTOR; INDUCIBLE NITRIC OXIDE SYNTHASE; IRON; IRON CHELATE;

APOPTOSIS; ARTICLE; AUTOIMMUNITY; BRAIN REGION; CARDIOVASCULAR RISK; CELL PROLIFERATION; CONCENTRATION (PARAMETERS); DISEASE COURSE; ENZYME INACTIVATION; GENE MUTATION; HEMOCHROMATOSIS; HYPERTENSION; HYPOTHESIS; IRON OVERLOAD; IRON TRANSPORT; LEG ULCER; LEG VEIN; MACROPHAGE; MOLECULAR MECHANICS; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR DOWN REGULATION; T LYMPHOCYTE;

ANIMALS; APOPTOSIS; DOWN-REGULATION; HUMANS; IRON OVERLOAD; LEG ULCER; MACROPHAGES; MODELS, BIOLOGICAL; MODELS, THEORETICAL; MULTIPLE SCLEROSIS; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE TYPE II; RECEPTORS, INTERFERON; T-LYMPHOCYTES; VARICOSE ULCER;

EID: 45649085636     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mehy.2008.02.009     Document Type: Article

References (38)

1. Zamboni P. The big idea: iron-dependent inflammation in venous disease and proposed parallels in multiple sclerosis. J Roy Soc Med 99 (2006) 1-5
2. Lanzara S., Catozzi L., De Palma M., et al. Mechanism of disease: the inflammatory chain in chronic venous disorders and genetic screening for prevention of venous leg ulcers. Acta Phlebol 7 (2006) 39-44
3. Hemmer B., Archelos J.J., and Hartung N.P. New concepts in the immunopathogenesis of multiple sclerosis. Nat Rev Neurosci 3 (2002) 291-301
4. Drayer B., Burger P., Hurwitz B., Dawson D., and Cain J. Reduced signal intensity on MR images of thalamus and putamen in multiple sclerosis: increased iron content?. Am J Roentgenol 149 (1987) 357-363
5. Ge Y., Jensen J.H., Lu H., et al. Quantitative assessment of iron accumulation in the deep gray matter of multiple sclerosis by magnetic field correlation imaging. Am J Neuroradiol 28 (2007) 1639-1644
6. Brass S.D., Benedict R.H.B., Weinstock-Guttman B., Munschauer F., and Bakshi R. Cognitive impairment is associated with subcortical magnetic resonance imaging grey matter T2 hypointensity in multiple sclerosis. Mult Scler 12 (2006) 437-444
7. Exley C., Mamutse G., Korchazhkina O., et al. Elevated urinary excretion of aluminium and iron in multiple sclerosis. Mult Scler 12 (2006) 533-540
8. Zamboni P., Scapoli G., Lanzara V., Izzo M., Fortini P., and Legnaro A. Serum iron and MMP-9 variation in limbs affected by chronic venous disease and venous leg ulcers. Dermatol Surg 31 (2005) 644-649
9. Zamboni P., Izzo M., and Tognazzo S. The overlapping of local iron overload and HFE mutation in venous leg ulcer pathogenesis. Free Radical Bio Med 40 (2006) 1869-1873
10. Zamboni P., Tognazzo S., and Izzo M. Hemochromatosis C282Y gene mutation increases the risk of venous leg ulceration. J Vasc Surg 42 (2005) 309-314
11. Rubio J.P., Bahlo M., Tubridy N., et al. Extended haplotype analysis in the HLA complex reveals an increased frequency of the HFE-C282Y mutation in individuals with multiple sclerosis. Hum Genet 114 (2004) 573-580
12. Ristić S., Lovrečić L., Brajenović-Milić B., et al. Mutations in the hemochromatosis gene (HFE) and multiple sclerosis. Neurosci Lett 383 (2005) 301-304
13. LeVine S.M., and Chakrabarty A. The role of iron in the pathogenesis of experimental allergic encephalomyelitis and multiple sclerosis. Ann NY Acad Sci 1012 (2004) 252-266
14. Yeoh-Ellerton S., and Stacey M.C. Iron and 8-isoprostane levels in acute and chronic wounds. J Invest Dermatol 121 (2003) 918-925
15. Ackerman Z., Seidenbaum M., Loewenthal E., and Rubinow A. Overload of iron in the skin of patients with varicose ulcers. Possible contributing role of iron accumulation in progression of the disease. Arch Dermatol 124 (1988) 1376-1378
16. Piñero D.J., and Connor J.R. Iron in the brain: an important contributor in normal and diseased states. Neuroscientist 6 (2000) 435-453
17. Anderson S.A., Shukaliak-Quandt J., Jordan E.K., et al. Magnetic resonance imaging of labeled T-cells in a mouse model of multiple sclerosis. Ann Neurol 55 (2004) 654-659
18. Grant S.M., Wiesinger J.A., Beard J.L., and Cantora M.T. Iron-deficient mice fail to develop autoimmune encephalomyelitis. J Nutr 133 (2003) 2635-2638
19. Leung S., Holbrook A., King B., et al. Differential inhibition of inducible T cell cytokine secretion by potent iron chelators. J Biomol Screen 10 (2005) 157-167
20. Deloire M.S.A., Touil T., Brochet B., Dousset V., Caillé J.M., and Petry K.G. Macrophage brain infiltration in experimental autoimmune encephalomyelitis is not completely compromised by suppressed T-cell invasion: in vivo magnetic resonance imaging illustration in effective anti-VLA-4 antibody treatment. Mult Scler 10 (2004) 540-548
21. Simka M. A potential role of interferon-gamma in the pathogenesis of venous leg ulcers. Med Hypotheses 67 (2006) 639-644
22. Schroder K., Hertzog P.J., Flavasi T., and Hume D.A. Interferon-γ: an overview of signals, mechanisms and functions. J Leukocyte Biol 75 (2004) 163-188
23. Bernabei P., Coccia E.M., Rigamonti L., et al. Interferon-γ receptor 2 expression as the deciding factor in human T, B, and myeloid cell proliferation or death. J Leukocyte Biol 70 (2001) 950-960
24. Bernabei P., Bosticardo M., Losana G., et al. IGF-1 down-regulates IFN-γR2 chain surface expression and desensitizes IFN-g/STAT-1 signaling in human T lymphocytes. Blood 102 (2003) 2933-2939
25. Arkins S., Rebeiz N., Brunke-Reese D.L., Birgyn A., and Kelly K.W. Interferon-γ inhibits macrophage insulin-like growth factor-1 synthesis at the transcriptional level. Mol Endocrinol 9 (1995) 350-360
26. Regis G., Bosticardo M., Conti L., et al. Iron regulates T-lymphocyte sensivity to the INF-γ/STAT1 signaling pathway in vitro and in vivo. Blood 105 (2005) 3214-3221
27. Allione A., Bernabei P., Bosticardo M., Ariotti S., Forni G., and Novelli F. Nitric oxide suppresses human T lymphocyte proliferation through INF-γ-dependent and INF-γ-independent induction of apoptosis. J Immunol 163 (1999) 4182-4191
28. Blesson S., Thiery J., Gaudin C., et al. Analysis of the mechanisms of human cytotoxic T lymphocyte response inhibition by NO. Int Immunol 14 (2002) 1169-1178
29. Sahrbacher U.C., Lechner F., Eugster H.P., Frei K., Lassmann H., and Fontana A. Mice with an inactivation of the inducible nitric oxide synthase gene are susceptible to experimental autoimmune encephalomyelitis. Eur J Immunol 28 (1998) 1332-1338
30. Oexle H., Kaser A., Möst J., et al. Pathways for the regulation of interferon-γ-inducible genes by iron in human monocytic cells. J Leukocyte Biol 74 (2003) 287-294
31. Kim Y.M., Chung H.T., Simmons R.L., and Billiar T.R. Cellular non-heme iron content is a determinant of nitric oxide-mediated apoptosis, necrosis, and caspase inhibition. J Biol Chem 275 (2000) 10954-10961
32. Mahidhara R.S., Hofman R.A., Huang S., et al. Nitric oxide-mediated inhibition of caspase-dependent T lymphocyte proliferation. J Leukocyte Biol 74 (2003) 403-411
33. Hooper D.C., Bagasra O., Marini J.C., et al. Prevention of experimental allergic encephalomyelitis by targeting nitric oxide and peroxynitrite: Implications for the treatment of multiple sclerosis. Proc Natl Acad Sci USA 94 (1997) 2528-2533
34. Clare A., FitzHenley M., Harris J., Hambleton I., and Serjeant G.R. Chronic leg ulceration in homozygous sickle cell disease: the role of venous incompetence. Brit J Haematol 119 (2002) 567-571
35. Mohan J.S., Vigilance J.E., Marshall J.M., Hambleton I.R., Reid H.L., and Serjeant G.R. Abnormal venous function in patients with homozygous sickle cell (SS) disease and chronic leg ulcers. Clin Sci (Lond) 98 (2000) 667-672
36. Chalchal H., Rodino W., Hussain S., et al. Impaired venous hemodynamics in a minority of patients with chronic leg ulcers due to sickle cell anemia. Vasa 30 (2001) 277-279
37. Mitchell K.M., Dotson A.L., Cool K.M., Chakrabarty A., Benedict S.H., and LeVine S.M. Deferiprone, an orally deliverable iron chelator, ameliorates experimental autoimmune encephalomyelitis. Mult Scler 13 (2007) 1118-1126
38. Lopez L., Dilley R.B., and Henriquez J.A. Cutaneous hyperpigmentation following venous sclerotherapy treated with deferoxamine mesylate. Dermatol Surg 27 (2001) 795-798